Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib for Keratinopathies
NCT06545695Phase 2Not yet recruiting
- Sponsor
- Northwestern University
- Start
- Jul 2027
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in epidermolytic ichthyosis (EI), palmoplantar keratoderma (PPK), pachyonychia congenita (PC), sponsored by Northwestern University. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
erlotinib
03
Conditions
epidermolytic ichthyosis (EI)palmoplantar keratoderma (PPK)pachyonychia congenita (PC)
Beyond the preview
Go deeper on NCT06545695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545695.